NERV

Minerva Neurosciences, Inc.

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 27

Established $75 million ATM offering to fund ongoing operations.

capital raise

70%

bearishMay 27

FDA feedback led to an extension of the Phase 3 relapse assessment phase.

regulatory action

50%

bearishMay 27

Potential for significant shareholder dilution via the new ATM program.

dilution risk

60%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

bearishMay 5

Reported a GAAP net loss of $125.4 million for the quarter.

earnings miss

70%

bullishMay 5

Completed private placement providing significant liquidity for Phase 3 trials.

capital raise

60%

bearishMay 5

Substantial warrant liability of $278.6 million poses significant dilution risk.

dilution risk

80%

Filing History

8-KMay 27, 2026

Minerva Neurosciences finds itself at a critical juncture, balancing a need for immediate capital with a lengthening clinical timeline. The company has secured a mechanism to raise up to $75 million, providing a necessary lifeline to support the C19 trial for roluperidone. However, the FDA's requirement to extend the relapse assessment phase creates a dual-edged sword: while it may lead to a more comprehensive data set, it simultaneously increases the financial burn and delays the potential for a commercial launch. Investors are now weighing the benefit of a more robust regulatory package against the risks of dilution and a prolonged wait for topline results in 2027 and 2028.

10-QMay 5, 2026

The Q1 2026 filing paints a picture of a high-stakes pharmaceutical venture at a critical juncture. The initiation of the C19 trial is a definitive positive step toward commercialization, but it simultaneously activates a period of increased spending and heightened risk. Investors are essentially betting on the clinical success of roluperidone to offset a complex capital structure characterized by significant warrant liabilities and a history of recurring losses. Ultimately, the impact of this filing is the establishment of a clear, albeit distant, catalyst calendar. The market must now weigh the potential for a category-defining CNS therapy against the very real possibility of capital exhaustion or regulatory failure. While the current liquidity provides a temporary bridge, the long-term viability of the company remains tethered to the H2 2027 data readout.